Bruton's tyrosine kinase inhibitors and cardiotoxicity: more than just atrial fibrillation

M Sestier, C Hillis, G Fraser, D Leong - Current oncology reports, 2021 - Springer
Abstract Purpose of Review The purpose of this review is to summarize the epidemiology,
mechanisms, and management of cardiovascular complications of Bruton's Tyrosine Kinase …

[PDF][PDF] Ibrutinib-associated cardiotoxicity: from the pharmaceutical to the clinical

R Dong, Y Yan, X Zeng, N Lin, B Tan - Drug Design, Development …, 2023 - Taylor & Francis
Ibrutinib is the first-in-class Bruton tyrosine kinase (BTK) inhibitor that has revolutionized the
treatment of B cell malignancies. Unfortunately, increased incidences of cardiotoxicity have …

Mitigating ibrutinib‐induced ventricular arrhythmia and cardiac dysfunction with metformin

P Li, D Liu, P Gao, M Yuan, Z Zhao, Y Zhang… - Cancer …, 2025 - Wiley Online Library
Background Ibrutinib is a first‐line drug that targets Bruton's tyrosine kinase for the treatment
of B cell cancer. However, cardiotoxicity induced by ibrutinib is a major side effect that limits …

Physical, Psychological, Social, and Spiritual Well-Being of Patients with Chronic Lymphocytic Leukemia and Their Caregivers: A Scoping Review.

E Gentry, C Passwater… - Journal of Oncology …, 2021 - search.ebscohost.com
Background: Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults,
and it has been shown to cause considerable symptom burden in both patients and their …

[HTML][HTML] Physical, Psychological, Social, and Spiritual Well-Being of Patients with Chronic Lymphocytic Leukemia and Their Caregivers: A Scoping Review

BSN Nikki Barkett - jons-online.com
Background: Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults,
and it has been shown to cause considerable symptom burden in both patients and their …

[引用][C] Ibrutinib-associated reversible cardiomyopathy

SH Liang, CF Chiu, LY Bai - Journal of oncology practice, 2019 - ascopubs.org
Discussion We believe that the myocardial dysfunction in our patient was cardiomyopathy
associated with ibrutinib for the following reasons: no history of congestive heart failure …